0.23%
8.33%
2.70%
-8.31%
8.00%
31.60%
52.75%
AI Spotlight on AZN
Company Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines.Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19.
The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia.It has a collaboration agreement with Regeneron Pharmaceuticals, Inc.to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc.
to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc.to develop and commercialize AZD5153.The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.
AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Market Data
| Last Price | 11340 |
| Change Percentage | 0.23% |
| Open | 11422 |
| Previous Close | 11314 |
| Market Cap ( Millions) | 175832 |
| Volume | 469960 |
| Year High | 13388 |
| Year Low | 9461 |
| M A 50 | 10636.3 |
| M A 200 | 11706.48 |
Financial Ratios
| FCF Yield | 3.10% |
| Dividend Yield | 1.31% |
| ROE | 16.57% |
| Debt / Equity | 77.51% |
| Net Debt / EBIDTA | 178.85% |
| Price To Book | 5.37 |
| Price Earnings Ratio | 33.67 |
| Price To FCF | 32.29 |
| Price To sales | 4.26 |
| EV / EBITDA | 16.37 |
News
- Jan -29 - Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
- Jan -29 - FDA expands Enhertu approval to include HER2-ultralow breast cancer patients
- Jan -29 - Should AstraZeneca Stock Be in Your Portfolio Pre-Q4 Earnings?
- Jan -28 - FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication
- Jan -27 - ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
- Jan -24 - Pharma Stock Roundup: JNJ's Q4 Earnings, FDA Nod to AZN, Daiichi Drug
- Jan -24 - Alphabet, Uber, Applied Materials, and 19 Other Picks From the Barron's Roundtable
- Jan -23 - AstraZeneca plans C$820 million (US$570m) investment in Canada to advance growing global hub and clinical delivery
- Jan -22 - Why Is AstraZeneca PLC (AZN) Among the Best Large-Cap Value Stocks to Buy in 2025?
- Jan -22 - AstraZeneca gains NICE nod for lung cancer drugs Tagrisso and Imfinzi
- Jan -21 - FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients
- Jan -21 - J&Js Lazcluze/Rybrevant combination obtains European approval to treat NSCLC
- Jan -20 - AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer
- Jan -20 - FDA Approves Two Breakthrough Cancer Treatments for AstraZeneca
- Jan -20 - AstraZeneca secures first BTK approval in first-line mantle cell lymphoma
- Jan -18 - Tariff threats, drug pricing will be 2 key pharma issues during Trump's first year
- Jan -18 - Ozempic, Xtandi among next 15 drugs selected for U.S. price talks
- Jan -17 - DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
- Jan -17 - Medicare to negotiate prices on 15 drugs, including Ozempic
- Jan -17 - Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Oncology
Expected Growth : 7 %
What the company do ?
Oncology from AstraZeneca PLC focuses on developing innovative cancer medicines to transform patient outcomes, improving diagnosis, treatment, and care.
Why we expect these perspectives ?
AstraZeneca's Oncology segment growth is driven by increasing demand for cancer treatments, strong pipeline of innovative therapies, and strategic acquisitions. Tagrisso's success in lung cancer, Imfinzi's growth in immuno-oncology, and Lynparza's dominance in PARP inhibitors contribute to the 7% growth. Additionally, emerging markets and partnerships with biotech companies fuel further expansion.
Segment n°2 -> Cardiovascular, Renal and Metabolism
Expected Growth : 5 %
What the company do ?
Cardiovascular, Renal and Metabolism (CVRM) is a therapy area from AstraZeneca PLC, focusing on innovative treatments for cardiovascular, renal, and metabolic diseases.
Why we expect these perspectives ?
AstraZeneca's 5% growth in Cardiovascular, Renal and Metabolism is driven by increasing prevalence of chronic diseases, innovative pipeline of medicines such as Farxiga and Brilinta, and strategic collaborations. Growing demand for diabetes and heart failure treatments, coupled with geographic expansion in emerging markets, further fuels growth.
Segment n°3 -> Rare Disease
Expected Growth : 8 %
What the company do ?
AstraZeneca PLC's Rare Disease segment focuses on developing treatments for rare genetic disorders, such as hypoparathyroidism and alpha-1 antitrypsin deficiency.
Why we expect these perspectives ?
AstraZeneca's Rare Disease segment growth is driven by increasing demand for orphan drugs, strong pipeline of gene therapies, and strategic acquisitions. The company's focus on precision medicine and investment in digital technologies also contribute to growth. Additionally, expanding into emerging markets and collaborations with patient advocacy groups further boost growth, resulting in an 8% growth rate.
Segment n°4 -> Respiratory and Immunology
Expected Growth : 4 %
What the company do ?
AstraZeneca's Respiratory and Immunology segment focuses on developing and commercializing medicines for respiratory diseases, such as asthma and COPD, and immunological disorders.
Why we expect these perspectives ?
AstraZeneca's Respiratory and Immunology segment growth is driven by increasing demand for Symbicort and Pulmicort, strong sales of Fasenra and Duaklir, and growing adoption of Bevespi Aerosphere. Additionally, the company's focus on emerging markets, strategic partnerships, and innovative pipeline contribute to the 4% growth rate.
Segment n°5 -> Alliance
Expected Growth : 3 %
What the company do ?
The Alliance is a collaboration between AstraZeneca PLC and academia to accelerate drug discovery and development in various therapeutic areas.
Why we expect these perspectives ?
AstraZeneca's alliance with Alliance drives 3% growth, fueled by increased R&D investments, expanded market reach, and enhanced pipeline diversification. Additionally, strategic partnerships and collaborations accelerate innovation, while cost savings from synergies and operational efficiencies further boost growth.
Segment n°6 -> Other Medicines
Expected Growth : 2 %
What the company do ?
AstraZeneca PLC's Other Medicines segment includes medicines for infection, neuroscience, and gastrointestinal diseases, as well as biosimilars and other specialty care products.
Why we expect these perspectives ?
AstraZeneca's Other Medicines segment growth is driven by increasing demand for chronic disease treatments, such as Symbicort and Nexium, as well as emerging market expansion. Strong pipeline development and strategic partnerships also contribute to growth. Additionally, the company's focus on digital healthcare and personalized medicine further supports segment growth.
Segment n°7 -> Vaccines and Immune Therapies
Expected Growth : 9 %
What the company do ?
AstraZeneca's Vaccines and Immune Therapies segment focuses on developing and commercializing vaccines and immune-mediated therapies to prevent and treat various diseases.
Why we expect these perspectives ?
AstraZeneca's Vaccines and Immune Therapies segment growth is driven by increasing demand for COVID-19 vaccines, strong sales of flu vaccines, and growing adoption of immune therapies for cancer and respiratory diseases. Additionally, strategic collaborations, investments in R&D, and expansion into emerging markets contribute to the segment's 9% growth.
Segment n°8 -> Collaboration
Expected Growth : 1 %
What the company do ?
AstraZeneca PLC's collaboration involves partnering with academia, biotechs, and pharma companies to accelerate innovation, share resources, and co-develop new medicines.
Why we expect these perspectives ?
AstraZeneca PLC's collaboration-driven growth is fueled by strategic partnerships, leveraging each other's strengths to accelerate innovation, expand market reach, and enhance R&D capabilities. This synergy enables the development of novel treatments, increases access to emerging markets, and drives revenue growth through co-promotion and co-development agreements.
Astrazeneca Plc Products
| Product Range | What is it ? |
|---|---|
| Tagrisso | A kinase inhibitor for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. |
| Imfinzi | A programmed death-ligand 1 (PD-L1) blocking antibody for the treatment of unresectable, stage III non-small cell lung cancer (NSCLC). |
| Lynparza | A poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of ovarian cancer, breast cancer, and pancreatic cancer. |
| Farxiga | A sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. |
| Symbicort | A combination of budesonide and formoterol fumarate dihydrate for the treatment of asthma and chronic obstructive pulmonary disease (COPD). |
| Pulmicort | A corticosteroid for the treatment of asthma. |
AstraZeneca PLC's Porter Forces
Threat Of Substitutes
AstraZeneca PLC faces moderate threat from substitutes due to the presence of alternative treatments and generic drugs in the market.
Bargaining Power Of Customers
AstraZeneca PLC has a diverse customer base, which reduces the bargaining power of individual customers, making it a low threat.
Bargaining Power Of Suppliers
AstraZeneca PLC relies on a few key suppliers for raw materials and services, giving them some bargaining power, making it a moderate threat.
Threat Of New Entrants
The pharmaceutical industry has high barriers to entry, including significant R&D investments and regulatory hurdles, making it a low threat for AstraZeneca PLC.
Intensity Of Rivalry
The pharmaceutical industry is highly competitive, with many established players and new entrants, making it a high-intensity rivalry for AstraZeneca PLC.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 42.24% |
| Debt Cost | 4.77% |
| Equity Weight | 57.76% |
| Equity Cost | 4.77% |
| WACC | 4.77% |
| Leverage | 73.12% |
AstraZeneca PLC : Quality Control
AstraZeneca PLC passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| SAN.PA | Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, … |
| GSK.L | GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the … |
| ROG.SW | Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products … |
| BAYN.DE | Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for … |
| NOVN.SW | Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Novartis
A-Score
1-Year Total Return ->
🥈
Sanofi
A-Score
1-Year Total Return ->
🥉
Roche
A-Score
1-Year Total Return ->
4
GSK
A-Score
1-Year Total Return ->
5
AstraZeneca
A-Score
1-Year Total Return ->
6
